Strategies for silencing human disease using RNA interference

Nature Reviews Genetics

Volumn 8, Issue 3, 2007, Pages 173-184

  Kim, Daniel H ^a   Rossi, John J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; APTAMER; COPPER ZINC SUPEROXIDE DISMUTASE; CYCLODEXTRIN; IMMUNOGLOBULIN HEAVY CHAIN; LENTIVIRUS VECTOR; LIPID; LIPOSOME; NANOCARRIER; PACLITAXEL; PEPTIDE; SMALL INTERFERING RNA; STABLE NUCLEIC ACID LIPID PARTICLE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

3' UNTRANSLATED REGION; ABSENCE OF SIDE EFFECTS; AMYOTROPHIC LATERAL SCLEROSIS; BASE PAIRING; DEGENERATIVE DISEASE; EWING SARCOMA; EYE DISEASE; GENE EXPRESSION; GENE INDUCTION; GENE OVEREXPRESSION; GENE SEQUENCE; GENE SILENCING; GENE TARGETING; GENETIC ALGORITHM; HUMAN; IMMUNOSTIMULATION; IN VIVO GENE TRANSFER; INNATE IMMUNITY; LIPID BILAYER; LIPOSOMAL GENE DELIVERY SYSTEM; LIVER CANCER; MESSENGER RNA SYNTHESIS; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; OPEN READING FRAME; POSTTRANSCRIPTIONAL GENE SILENCING; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FAMILY; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RNA INTERFERENCE; RNA STRUCTURE; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; STRUCTURE ANALYSIS; TRANSCRIPTION TERMINATION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALS; EYE DISEASES; GENE THERAPY; HUMANS; NEOPLASMS; NEURODEGENERATIVE DISEASES; RNA INTERFERENCE; RNA, SMALL INTERFERING; VIRUS DISEASES;

ANIMALIA;

EID: 33847036990     PISSN: 14710056     EISSN: 14710064     Source Type: Journal    
DOI: 10.1038/nrg2006     Document Type: Review

References (93)

1. Fire, A. et al. Potent and specific genetic interference by double stranded RNA in Caenorhabditis elegans. Nature 391, 806-811 (1998). This Nobel Prize-winning landmark paper provides the first description of the phenomenon of RNAi.
2. Elbashir, S. M. et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494-498 (2001). This work provides the first description of RNAi in mammalian cells.
3. Hannon, G. J. & Rossi, J. J. Unlocking the potential of the human genome with RNA interference. Nature 431, 371-378 (2004).
4. Check, E. A crucial test. Nature Med. 11, 243-244 (2005).
5. McFarland, T. J., Zhang, Y., Appukuttan, B. & Stout, J. T. Gene therapy for proliferative ocular diseases. Expert Opin. Biol. Ther. 4, 1053-1058 (2004).
6. Bitko, V., Musiyenko, A., Shulyayeva, O. & Barik, S. Inhibition of respiratory viruses by nasally administered siRNA. Nature Med. 11, 50-55 (2005).
7. Rossi, J. J. RNAi as a treatment for HIV-1 infection. Biotechniques 40, s25-s29 (2006).
8. Dykxhoorn, D. M. & Lieberman, J. Silencing viral infection. PLoS Med. 3, e242 (2006).
9. Raoul, C., Barker, S. D. & Aebischer, P. Viral-based modeling and correction of neurodegenerative diseases by RNA interference. Gene Ther. 13, 487-495 (2006).
10. Pai, S. I. et al. Prospects of RNA interference therapy for cancer. Gene Ther. 13, 464-477 (2006).
11. Amarzguioui, M., Rossi, J. J. & Kim, D. Approaches for chemically synthesized siRNA and vector-mediated RNAi. FEBS Lett. 579, 5974-5981 (2005).
12. de Veer, M. J., Sledz, C. A. & Williams, B. R. Detection of foreign RNA: implications for RNAi. Immunol. Cell Biol. 83, 224-228 (2005).
13. Grimm, D. et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441, 537-541 (2006). This paper describes the in vivo toxicity of long-term, high-level shRNA expression in mice.
14. Behlke, M. A. Progress towards in vivo use of siRNAs. Mol. Ther. 13, 644-670 (2006).
15. Meister, G. & Tuschl, T. Mechanisms of gene silencing by double-stranded RNA. Nature 431, 343-349 (2004).
16. Matzke, M. A. & Birchler, J. A. RNAi-mediated pathways in the nucleus. Nature Rev. Genet. 6, 24-35 (2005).
17. Wassenegger, M. The role of the RNAi machinery in heterochromatin formation. Cell 122, 13-16 (2005).
18. Zamore, P. D., Tuschl, T., Sharp, P. A. & Bartel, D. P. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 101, 25-33 (2000).
19. Bernstein, E., Caudy, A. A., Hammond, S. M. & Hannon, G. J. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 409, 363-366 (2001).
20. Martinez, J., Patkaniowska, A., Urlaub, H., Luhrmann, R. & Tuschl, T. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 110, 563-574 (2002).
21. Liu, J. et al. Argonaute2 is the catalytic engine of mammalian RNAi. Science 305, 1437-1441 (2004).
22. Matranga, C., Tomari, Y., Shin, C., Bartel, D. P. & Zamore, P. D. Passenger-strand cleavage facilitates assembly of siRNA into AGO2-containing RNAi enzyme complexes. Cell 123, 607-620 (2005).
23. Rand, T. A., Petersen, S., Du, F. & Wang, X. Argonaute2 cleaves the anti-guide strand of siRNA during RISC activation. Cell 123, 621-629 (2005).
24. Parker, J. S., Roe, S. M. & Barford, D. Structural insights into mRNA recognition from a PIWI domain-siRNA guide complex. Nature 434, 663-666 (2005).
25. Ma, J. B., Ye, K. & Patel, D. J. Structural basis for overhang-specific small interfering RNA recognition by the PAZ domain. Nature 429, 318-322 (2004).
26. Elbashir, S. M., Lendeckel, W. & Tuschl, T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 15, 188-200 (2001).
27. Orban, T. I. & Izaurralde, E. Decay of mRNAs targeted by RISC requires XRN1, the Ski complex, and the exosome. RNA 11, 459-469 (2005).
28. Hutvagner, G. & Zamore, P. D. A microRNA in a multiple-turnover RNAi enzyme complex. Science 297, 2056-2060 (2002).
29. Bartel, D. P. & Chen, C. Z. Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. Nature Rev. Genet. 5, 396-400 (2004).
30. Lee, R. C., Feinbaum, R. L. & Ambros, V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75, 843-854 (1993).
31. Wightman, B., Ha, I. & Ruvkun, G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 75, 855-862 (1993).
32. Liu, J., Valencia-Sanchez, M. A., Hannon, G. J. & Parker, R. MicroRNA-dependent localization of targeted mRNAs to mammalian P-bodies. Nature Cell Biol. 7, 719-723 (2005).
33. Yekta, S., Shih, I. H. & Bartel, D. P. MicroRNA-directed cleavage of Hoxb8 mRNA. Science 304, 594-596 (2004).
34. Lee, Y. et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 23, 4051-4060 (2004).
35. Borchert, G. M., Lanier, W. & Davidson, B. L. RNA polymerase III transcribes human microRNAs. Nature Struct. Mol. Biol. 13, 1097-1101 (2006).
36. Lee, Y. et al. The nuclear RNase III Drosha initiates microRNA processing. Nature 425, 415-419 (2003).
37. Gregory, R. I. et al. The Microprocessor complex mediates the genesis of microRNAs. Nature 432, 235-240 (2004).
38. Yi, R., Qin, Y., Macara, I. G. & Cullen, B. R. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev. 17, 3011-3016 (2003).
39. Lund, E., Guttinger, S., Calado, A., Dahlberg, J. E. & Kutay, U. Nuclear export of microRNA precursors. Science 303, 95-98 (2004).
40. Chendrimada, T. P. et al. TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature 436, 740-744 (2005).
41. Lee, Y. et al. The role of PACT in the RNA silencing pathway. EMBO J. 25, 522-532 (2006).
42. Preall, J. B. & Sontheimer, E. J. RNAi: RISC gets loaded. Cell 123, 543-245 (2005).
43. Lewis, B. P., Burge, C. B. & Bartel, D. P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120, 15-20 (2005).
44. Silva, J. M. et al. Second-generation shRNA libraries covering the mouse and human genomes. Nature Genet. 37, 1281-1288 (2005).
45. Morris, K. V., Chan, S. W., Jacobsen, S. E. & Looney, D. J. Small interfering RNA-induced transcriptional gene silencing in human cells. Science 305, 1289-1292 (2004).
46. Kim, D. H., Villeneuve, L. M., Morris, K. V. & Rossi, J. J. Argonaute-1 directs siRNA-mediated transcriptional gene silencing in human cells. Nature Struct. Mol. Biol. 13, 793-797 (2006).
47. Janowski, B. A. et al. Involvement of AGO1 and AGO2 in mammalian transcriptional silencing. Nature Struct. Mol. Biol. 13, 787-792 (2006).
48. Ting, A. H., Schuebel, K. E., Herman, J. G. & Baylin, S. B. Short double-stranded RNA induces transcriptional gene silencing in human cancer cells in the absence of DNA methylation. Nature Genet. 37, 906-910 (2005).
49. Weinberg, M. S. et al. The antisense strand of small interfering RNAs directs histone methylation and transcriptional gene silencing in human cells. RNA 12, 256-262 (2006).
50. Vastenhouw, N. L. et al. Gene expression: long-term gene silencing by RNAi. Nature 442, 882 (2006).
51. Kim, D. H. et al. Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nature Biotechnol. 23, 222-226 (2005).
52. Siolas, D. et al. Synthetic shRNAs as potent RNAi triggers. Nature Biotechnol. 23, 227-231 (2005).
53. Marques, J. T. et al. A structural basis for discriminating between self and nonself doublestranded RNAs in mammalian cells. Nature Biotechnol. 24, 559-565 (2006).
54. Brummelkamp, T. R., Bernards, R. & Agami, R. A system for stable expression of short interfering RNAs in mammalian cells. Science 296, 550-553 (2002).
55. Paddison, P. J., Caudy, A. A., Bernstein, E., Hannon, G. J. & Conklin, D. S. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev. 16, 948-958 (2002). References 54 and 55 describe stable expression systems for RNAi.
56. Zeng, Y., Wagner, E. J. & Cullen, B. R. Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells. Mol. Cell 9, 1327-1333 (2002).
57. Sarnow, P., Jopling, C. L., Norman, K. L., Schutz, S. & Wehner, K. A. MicroRNAs: expression, avoidance and subversion by vertebrate viruses. Nature Rev. Microbiol. 4, 651-659 (2006).
58. Jackson, A. L. et al. Widespread siRNA 'off-target' transcript silencing mediated by seed region sequence complementarity. RNA 12, 1179-1187 (2006).
59. Birmingham, A. et al. 3' UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nature Methods 3, 199-204 (2006).
60. Hornung, V. et al. Sequence-specific potent induction of IFN-? by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nature Med. 11, 263-270 (2005). This work describes the detection of immunostimulatory motifs in siRNA sequences through TLRs.
61. Manche, L., Green, S. R., Schmedt, C. & Mathews, M. B. Interactions between double-stranded RNA regulators and the protein kinase DAI. Mol. Cell. Biol. 12, 5238-5248 (1992).
62. Seth, R. B., Sun, L. & Chen, Z. J. Antiviral innate immunity pathways. Cell Res. 16, 141-147 (2006).
63. Judge, A. D. et al. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nature Biotechnol. 23, 457-462 (2005).
64. Kim, D. H. et al. Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. Nature Biotechnol. 22, 321-325 (2004).
65. Robbins, M. A. et al. Stable expression of shRNAs in human CD34+ progenitor cells can avoid induction of interferon responses to siRNAs in vitro. Nature Biotechnol. 24, 566-571 (2006).
66. An, D. S. et al. Optimization and functional effects of stable short hairpin RNA expression in primary human lymphocytes via lentiviral vectors. Mol. Ther. 14, 494-504 (2006).
67. Czauderna, F. et al. Structural variations and stabilizing modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res. 31, 2705-2716 (2003).
68. Morrissey, D. V. et al. Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology 41, 1349-1356 (2005).
69. Chiu, Y. L. & Rana, T. M. siRNA function in RNAi: a chemical modification analysis. RNA 9, 1034-1048 (2003).
70. Morrissey, D. V. et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nature Biotechnol. 23, 1002-1007 (2005).
71. Soutschek, J. et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432, 173-178 (2004). This work describes a straightforward and effective method for intravenous systemic delivery of RNAi.
72. Zimmermann, T. S. et al. RNAi-mediated gene silencing in non-human primates. Nature 441, 111-114 (2006). This paper describes the potency and longevity of systemic delivery of RNAi in non-human primates.
73. Song, E. et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nature Biotechnol. 23, 709-717 (2005).
74. McNamara, J. O. et al. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nature Biotechnol. 24, 1005-1015 (2006).
75. Chu, T. C., Twu, K. Y., Ellington, A. D. & Levy, M. Aptamer mediated siRNA delivery. Nucleic Acids Res. 34, e73 (2006).
76. Hu-Lieskovan, S., Heidel, J. D., Bartlett, D. W., Davis, M. E. & Triche, T. J. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res. 65, 8984-8992 (2005).
77. Morris, K. V. & Rossi, J. J. Lentiviral-mediated delivery of siRNAs for antiviral therapy. Gene Ther. 13, 553-558 (2006).
78. Grimm, D. & Kay, M. A. Therapeutic short hairpin RNA expression in the liver: viral targets and vectors. Gene Ther. 13, 563-575 (2006).
79. Lee, N. S. et al. Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nature Biotechnol. 20, 500-505 (2002).
80. Novina, C. D. et al. siRNA-directed inhibition of HIV-1 infection. Nature Med. 8, 681-686 (2002).
81. Jacque, J., Triques, K. & Stevenson, M. Modulation of HIV-1 replication by RNA interference. Nature 418, 435-438 (2002).
82. Coburn, G. A. & Cullen, B. R. Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference. J. Virol. 76, 9225-9231 (2002).
83. Martinez, J. & Tuschl, T. RISC is a 5′ phosphomonoester- producing RNA endonuclease. Genes Dev. 18, 975-980 (2004).
84. Huang, Y. et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nature Med. 2, 1240-1243 (1996).
85. Li, M. J. et al. Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. Mol. Ther. 12, 900-909 (2005).
86. Zhang, W. et al. Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene. Nature Med. 11, 56-62 (2005).
87. Palliser, D. et al. An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature 439, 89-94 (2006). This paper describes the efficacy of topical delivery of RNAi as a microbicide.
88. Xia, H. et al. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nature Med. 10, 816-820 (2004).
89. Raoul, C. et al. Lentiviral-mediated silencing of Sod1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nature Med. 11, 423-428 (2005).
90. Ralph, G. S. et al. Silencing mutant Sod1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nature Med. 11, 429-433 (2005).
91. Pai, S. I. et al. Prospects of RNA interference therapy for cancer. Gene Ther. 13, 464-477 (2006).
92. Landen, C. N. et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 65, 6910-6918 (2005).
93. Dykxhoorn, D. M. & Lieberman, J. Knocking down disease with siRNAs. Cell 126, 231-235 (2006).